<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05004909</url>
  </required_header>
  <id_info>
    <org_study_id>TretandTCAPeeling</org_study_id>
    <nct_id>NCT05004909</nct_id>
  </id_info>
  <brief_title>Effectivity of 1 Finger Tip Unit Compared to 2 Finger Tip Units 0.05% Tretinoin Cream</brief_title>
  <official_title>Effectivity of 1 Finger Tip Unit Compared to 2 Finger Tip Units 0.05% Tretinoin Cream Before and After 30% Trichloroacetic Acid Chemical Peeling on Aging Skin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr.dr.Irma Bernadette, SpKK (K)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will compare the efficacy of using one fingertip unit and two fingertip&#xD;
      units of 0.05% before and after 30% trichloroacetic acid chemical peel procedure for facial&#xD;
      skin rejuvenation in 35-60 years old female patients with Glogau II-III skin classification.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an experimental study with a randomized controlled trial (RCT) design on&#xD;
      patients who met the inclusion criteria. Group A will receive pretreatment in the form of&#xD;
      0.05% tretinoin cream which is used as much as one fingertip unit every night, and group B&#xD;
      will receive the same cream which should be used as much as two fingertip units. This cream&#xD;
      will be used for two weeks before the patients receive a chemical peeling therapy using 30%&#xD;
      trichloroacetic acid. The results of therapy will mainly be assessed based on the Dermoscopic&#xD;
      Photoaging Scale (DPAS), as well as visual analog scale (VAS) for subjective symptoms and&#xD;
      Clinician Erythema Assessment Scale (CEA) for erythema.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Photoaged Skin Condition</measure>
    <time_frame>Baseline(pre-chemical peeling procedure), immediately after chemical peeling procedure, and 4 weeks after chemical peeling procedure</time_frame>
    <description>using dermoscopic photoaging scale (DPAS). This DPAS assessment is based on yes or no rules on 11 criteria in four facial regions, namely left malar, right malar, forehead, and chin. The criteria were yellowish discoloration, white line, lentigo, hypo- and hyper-pigmented macules, telangiectasia, yellow papules, actinic keratosis, senile comedones, deep wrinkle, superficial wrinkle, and criss-cross wrinkle. Score range is 0-44 points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Subjective Pain Evaluation</measure>
    <time_frame>Baseline(pre-chemical peeling procedure), immediately after chemical peeling procedure, and 4 weeks after chemical peeling procedure</time_frame>
    <description>using Visual Analog Scale (VAS). Scale range is 0-10, 0 indicates no pain and 10 indicates severe pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Erythema Degree</measure>
    <time_frame>Baseline(pre-chemical peeling procedure), immediately after chemical peeling procedure, and 4 weeks after chemical peeling procedure</time_frame>
    <description>using Clinician Erythema Assessment Scale (CEA). Scale range is 0-4, 0 indicates no erythema and 4 indicates severe erythema</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Skin Thickness</measure>
    <time_frame>Baseline(pre-chemical peeling procedure) and 4 weeks after chemical peeling procedure</time_frame>
    <description>Evaluation with USG of epidermal and dermal layer (in pixels)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Photoaging</condition>
  <arm_group>
    <arm_group_label>1 Fingertip Unit 0.05% Tretinoin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects were randomized to receive the instructions to use 1 fingertip unit of 0.05% tretinoin cream for 2 weeks before the first chemical peeling. After that, this therapy is instructed to be used for 4 weeks after the chemical peeling procedure with 30% trichloroacetic acid until the scheduled evaluation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Fingertip Units 0.05% Tretinoin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were randomized to receive the instructions to use 2 fingertip units of 0.05% tretinoin cream for 2 weeks before the first chemical peeling. After that, this therapy is instructed to be used for 4 weeks after the chemical peeling procedure with 30% trichloroacetic acid until the scheduled evaluation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.05% Tretinoin</intervention_name>
    <description>Topical 0.05% tretinoin cream applied daily every night by the subjects according to assigned randomization</description>
    <arm_group_label>1 Fingertip Unit 0.05% Tretinoin</arm_group_label>
    <arm_group_label>2 Fingertip Units 0.05% Tretinoin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients aged 35-60 years old&#xD;
&#xD;
          -  Patients with Glogau II-III skin classification&#xD;
&#xD;
          -  Patients are willing to participate in the study and sign an informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with hypertrophic scars or keloid on the face&#xD;
&#xD;
          -  Patients with open wound or infection on the face&#xD;
&#xD;
          -  History of other topical treatment on the face within 1 month of enrollment&#xD;
&#xD;
          -  Pregnant or breastfeeding mother&#xD;
&#xD;
          -  Patients and/or their families are not willing to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irma BS Sitohang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fakultas Kedokteran Universitas Indonesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Irma BS Sitohang, MD</last_name>
    <phone>+62818130761</phone>
    <email>irma_bernadette@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Indonesia dr. Cipto Mangunkusumo Hospital</name>
      <address>
        <city>Jakarta</city>
        <state>Jakarta Pusat</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Dr.dr.Irma Bernadette, SpKK (K)</investigator_full_name>
    <investigator_title>Irma Bernadette S. Sitohang, MD, PhD - Head of Cosmetic Dermatology Division, Department of Dermatology and Venereology, Faculty of Medicine, Universitas Indonesia, dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia</investigator_title>
  </responsible_party>
  <keyword>Photoaging</keyword>
  <keyword>Tretinoin</keyword>
  <keyword>Trichloroacetic Acid</keyword>
  <keyword>Chemical Peeling</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

